News | Molecular Imaging | May 28, 2020

New radiopharmaceutical intended for PET imaging of metastatic breast cancer patients

New radiopharmaceutical intended for PET imaging of metastatic breast cancer patients

May 27, 2020 — PETNET Solutions, Inc., a Siemens Healthineers company, and Zionexa USA, a wholly owned subsidiary of Zionexa SAS, have announced that the Food and Drug Administration (FDA) has approved Cerianna (fluoroestradiol F 18) injection for intravenous use. Cerianna (fluoroestradiol F 18) is a molecular imaging agent indicated for use in positron emission tomography (PET) imaging for the detection of estrogen receptor-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. Cerianna (fluoroestradiol F 18) is the first FDA-approved F-18 PET imaging agent specifically indicated for use in patients with recurrent or metastatic breast cancer.

Cerianna (fluoroestradiol F 18) will be commercially available beginning in late 2020/early 2021 through PETNET Solutions, Inc., Zionexa USA’s manufacturer and exclusive commercial distributor in the U.S. Additional manufacturing sites will be added as each site receives regulatory approval to commence manufacturing.  

“PETNET Solutions, Inc., is proud to work with Zionexa USA as the exclusive U.S. commercial supplier making Cerianna (fluoroestradiol F 18) accessible to imaging centers and their breast cancer patients,” said Barry Scott, head of PETNET Solutions, Inc. “Our extensive network of radiopharmacies enables us to increase access to cutting-edge radiotracers such as Cerianna (fluoroestradiol F 18), helping healthcare facilities address the challenge of recurrent and metastatic breast cancer.”

“Zionexa is pleased to be able to make Cerianna (fluoroestradiol F 18) commercially available through the extensive manufacturing network of PETNET Solutions, Inc.,” said Peter Webner, chief executive officer of Zionexa USA. “PETNET has been a great partner to Zionexa and has surpassed our expectations as a contract manufacturer. Cerianna (fluoroestradiol F 18) will provide clinicians with additional, previously unavailable data on the estrogen receptor status of tumors across the patient’s entire body, providing additional data to enhance therapeutic decision-making.”

For more information: www.zionexa.com/


Related Content

News | Radiation Therapy

October 2, 2023 — A type of head and neck cancer predominantly diagnosed in people who reside in low- and middle-income ...

Time October 02, 2023
arrow
News | Radiation Oncology

October 2, 2023 — Two liquid biopsy tests that look for the presence of human papillomavirus (HPV) in the blood ...

Time October 02, 2023
arrow
News | Prostate Cancer

October 1, 2023 — The presence of a clinical navigator to act as a liaison between people with prostate cancer and the ...

Time October 01, 2023
arrow
News | ASTRO

October 1, 2023 — The 2023 Abstract Award winners have been announced by the American Society for Radiation Oncology ...

Time October 01, 2023
arrow
News | Women's Health

October 1, 2023 — In a first-of-its-kind study, people with breast cancer who underwent implant-based breast ...

Time October 01, 2023
arrow
News | Stereotactic Body Radiation Therapy (SBRT)

October 1, 2023 — Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted ...

Time October 01, 2023
arrow
News | Women's Health

October 1, 2023 — People who engage in sexual activity or vaginal dilation after chemoradiation treatment for cervical ...

Time October 01, 2023
arrow
News | Information Technology

September 29, 2023 — Fuse Oncology (Fuse) a trailblazing leader in radiation oncology software solutions, unveils their ...

Time September 29, 2023
arrow
News | Prostate Cancer

September 29, 2023 — People with intermediate risk, localized prostate cancer can be treated as effectively using fewer ...

Time September 29, 2023
arrow
News | Oncology Information Management Systems (OIMS)

September 29, 2023 — RaySearch will be showcasing the latest software innovations at ASTRO in San Diego, California ...

Time September 29, 2023
arrow
Subscribe Now